PATENT CLAIM ANALYSIS

Application Number: 15742867
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "317000"]

Abstract:
The invention relates to antagonists of integrin α4 and their use in pharmaceutical compositions, primarily topically administered ophthalmic compositions. The pharmaceutical compositions are useful for treating ocular inflammatory conditions, such as dry eye disease, non-infectious uveitis (e.g., anterior, intermediate, posterior, pan-uveitis), non-infectious conjunctivitis, iritis, or scleritis in animals, and particularly mammals, including humans.

Claim (Index 4):
A pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt, ester, hydrate, solvate, polymorph, optical isomer, racemate, diastereoisomer or enantiomer thereof, and one or more pharmaceutically acceptable excipients;\n wherein the composition is suitable for ocular administration.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 86.0
- Lexical Diversity: 1.38
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15676968', '13304292', '13601258', '15080893', '14857758']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7835297328468382
- 35 USC 102 Novelty (BERT): 0.5065645095510829
- Combined Prediction Score: 0.7558332105172627
- Mean Citation Score: 255.577264
- Max Citation Score: 266.30417
- Similarity Product: 184.61944533160568

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test